Leukemia

Black and Hispanic patients with cancer demonstrated a higher risk for COVID-19 infection than their white counterparts, according to results of a study presented during ASCO Quality Care Symposium.

A phase 3 trial of omidubicel has shown the graft modality superior to standard umbilical cord blood for bone marrow transplantation in patients with hematologic malignancies, according to topline data released by the agent’s manufacturer.

The FDA granted orphan drug designation to oNKord, an investigational natural killer cell-based therapy, for the treatment of multiple myeloma, according to the agent’s manufacturer.

Achievement of minimal residual disease negativity appeared associated with superior DFS and OS among patients with acute myeloid leukemia, according to results of a meta-analysis published in JAMA Oncology.

The increasing number of deaths in the United States due to COVID-19 has underscored the need to identify populations at elevated risk for virus-related mortality.

Last week, President Donald J. Trump announced that he and First Lady Melania Trump tested positive for SARS-CoV-2. It was the top story in infectious disease.

The FDA granted fast track designation to CLBR001 + SWI019, a chimeric antigen receptor T-cell therapy designed to treat B-cell malignancies, according to the agent’s developer.

“Berlin patient” Timothy Ray Brown, the first person cured of HIV, has died following a recurrence of leukemia, according to the International AIDS Society.

A trial of ponatinib for certain patients with chronic myeloid leukemia demonstrated a trend toward dose-dependent efficacy and safety, according to study results presented at Society of Hematologic Oncology Annual Meeting.

Minimal residual disease persistence prior to allogeneic hematopoietic stem cell transplant influenced OS and RFS among patients with acute leukemia, according to study results presented at Society of Hematologic Oncology Annual Meeting.